Big Food vs. Big Pharma: Companies Bet on Snacking Just as Weight Loss Drugs Boom
October 2, 2023
Major food companies are doubling down on snacking as consumer habits shift, but the rise of weight loss drugs like Wegovy and Ozempic poses a potential threat to their growth. These drugs, known as GLP-1 agonists, suppress appetites and can lead to aversions to sugary and fatty foods, which are core offerings of many big snack brands. While the pharmaceuticals’ success could lead to slower sales for snack producers, their high cost and other factors suggest that the immediate impact may be limited, giving food companies time to adapt.
Recent News
After a 60-Year Run, GM Is Retiring the Chevy Malibu
It’s the end of an era for the Chevrolet Malibu as General Motors is shutting its production down to focus efforts on a new electric vehicle.
Applebee’s Enters ‘Burger Wars’ Amid Sales Slump
Applebee’s thinks it has the right burger formula to lure back customers.
Tesla Axes All but 3 Jobs Out of 3,400 Listed Roles in North America
Tesla has axed more than 3,400 job postings, leaving only three in North America.
AstraZeneca Pulls COVID-19 Vaccine Amid Disappearing Demand
AstraZeneca is the latest company to feel the COVID-19 vaccine demand slump.